Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Exact Sciences, Pfizer to Comarket Cologuard

Exact Sciences, Pfizer to Comarket Cologuard

Aug 22, 2018
|
staff reporter

NEW YORK (GenomeWeb) – Exact Sciences and Pfizer announced today that they have entered into an agreement to copromote Exact's colorectal cancer screening test Cologuard.

Investors welcomed the news by sending Exact's shares up more than 22 percent to $61.20 in morning trading on the Nasdaq.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Plans Out

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

CovidNudge Numbers

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

Science Papers Propose Group to Discuss Genome-Editing Tools, Markers of Diabetes Drug Response, More

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

Not Counting These

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

What's Popular?

In Business News

  1. Genetics Testing Firm Prenetics Receives $15M Investment From Apis Partners, Alibaba

  2. Foundation Medicine, Takeda Collaborate to Develop CDx for NSCLC Therapies

  3. Roche Gets FDA Emergency Use Authorization for Rapid Coronavirus, Flu Test

  4. Qiagen Acquires Remaining Stake in NeuMoDx Molecular for $248M

  5. JumpCode Genomics Emerges From Stealth Mode With CRISPR-Based Library Prep Kits

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.